Wells Fargo & Company Nurix Therapeutics, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 40,803 shares of NRIX stock, worth $889,097. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,803

Previous 25,349 60.96%

Holding current value

$889,097

Previous $529,000 73.16%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$18.93 - $25.69 $292,544 - $397,013	15,454 Added 60.96%	40,803 $916,000
Q2 2024 Aug 13, 2024	BUY	$12.02 - $21.3 $50,267 - $89,076	4,182 Added 19.76%	25,349 $529,000
Q1 2024 May 10, 2024	BUY	$7.77 - $15.66 $15,625 - $31,492	2,011 Added 10.5%	21,167 $311,000
Q4 2023 Feb 09, 2024	SELL	$4.25 - $10.71 $63,282 - $159,471	-14,890 Reduced 43.73%	19,156 $197,000
Q3 2023 Nov 13, 2023	SELL	$7.86 - $10.08 $46,900 - $60,147	-5,967 Reduced 14.91%	34,046 $267,000
Q2 2023 Aug 15, 2023	BUY	$8.7 - $13.28 $57,272 - $87,422	6,583 Added 19.69%	40,013 $399,000
Q1 2023 May 12, 2023	BUY	$8.56 - $13.26 $271,608 - $420,739	31,730 Added 1866.47%	33,430 $296,000
Q4 2022 Feb 13, 2023	SELL	$9.86 - $14.59 $9,130 - $13,510	-926 Reduced 35.26%	1,700 $18,000
Q3 2022 Nov 14, 2022	SELL	$12.33 - $19.81 $4,118 - $6,616	-334 Reduced 11.28%	2,626 $34,000
Q2 2022 Aug 12, 2022	SELL	$7.88 - $14.82 $61,196 - $115,092	-7,766 Reduced 72.4%	2,960 $38,000
Q1 2022 May 16, 2022	SELL	$12.94 - $29.65 $132,376 - $303,319	-10,230 Reduced 48.82%	10,726 $150,000
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $169,204 - $220,869	6,402 Added 43.99%	20,956 $607,000
Q3 2021 Nov 15, 2021	BUY	$22.71 - $36.69 $323,254 - $522,245	14,234 Added 4448.13%	14,554 $437,000
Q2 2021 Aug 16, 2021	SELL	$24.21 - $35.89 $326,713 - $484,335	-13,495 Reduced 97.68%	320 $9,000
Q1 2021 May 13, 2021	SELL	$26.98 - $50.17 $909,010 - $1.69 Million	-33,692 Reduced 70.92%	13,815 $430,000
Q4 2020 Feb 09, 2021	BUY	$22.85 - $48.44 $280,163 - $593,922	12,261 Added 34.79%	47,507 $1.56 Million
Q3 2020 Nov 05, 2020	BUY	$16.05 - $34.91 $565,698 - $1.23 Million	35,246 New	35,246 $1.23 Million

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.03B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Nurix Therapeutics, Inc. Transaction History